Cumberland Pharmaceuticals Inc. (CPIX) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Cumberland Pharmaceuticals Inc. (CPIX) closed at USD 7.49 on 2026-10-14, a change of +192.7 % over the past year, with a market capitalization of USD 112.97M.

Cumberland Pharmaceuticals Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Cumberland Pharmaceuticals Inc. key figures

Previous close

USD 7.49 (2026-10-14)

1-year change

+192.7 %

Market cap

USD 112.97M

Enterprise value

USD 113.49M

P/E ratio (trailing)

-11.42

P/E ratio (forward)

53.86

EPS (trailing)

-0.66

EPS (forward)

0.14

PEG ratio

1.67

Price to book

6.48

Revenue growth

-56.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.46

Employees

88

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Cumberland Pharmaceuticals Inc. and compare it with other stocks.